Alethia Young
Stock Analyst at Cantor Fitzgerald
(3.72)
# 790
Out of 4,722 analysts
144
Total ratings
55.65%
Success rate
32.31%
Average return
Main Sectors:
Stocks Rated by Alethia Young
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $15.16 | - | 5 | Jul 5, 2024 | |
ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $19.95 | - | 5 | Jun 20, 2024 | |
REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $740.29 | +14.82% | 9 | Oct 16, 2023 | |
ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $1.86 | +867.74% | 6 | Sep 12, 2023 | |
CRIS Curis | Reiterates: Overweight | $60 | $3.52 | +1,604.55% | 3 | Sep 7, 2023 | |
ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $4.33 | +108.09% | 2 | Aug 22, 2023 | |
VSTM Verastem | Reiterates: Overweight | $34 | $6.14 | +453.75% | 2 | Jul 6, 2023 | |
BIIB Biogen | Maintains: Neutral | $427 → $327 | $151.69 | +115.57% | 7 | Oct 15, 2021 | |
ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $4.53 | +562.25% | 4 | Jul 23, 2021 | |
RAPT RAPT Therapeutics | Maintains: Overweight | $51 → $71 | $1.45 | +4,796.55% | 2 | Jun 14, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $281 | $411.96 | -31.79% | 5 | Jun 11, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $1.81 | +343.21% | 1 | Mar 8, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.67 | +5,785.89% | 3 | Feb 25, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $262.98 | +12.18% | 9 | Feb 3, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $89.41 | -3.81% | 3 | Oct 29, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $28.70 | +67.25% | 4 | Oct 28, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $14.50 | +106.90% | 1 | Oct 12, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $35.85 | +100.86% | 8 | Jul 31, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $2.12 | +135.99% | 5 | Jun 2, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $73.32 | +36.39% | 6 | May 19, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $28 → $24 | $0.53 | +4,402.81% | 3 | May 5, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $134.41 | +49.54% | 6 | Apr 20, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $44.84 | +89.56% | 5 | Apr 8, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $8.37 | +282.32% | 1 | Mar 6, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $126.24 | +71.89% | 12 | Feb 27, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $14.50 | +231.03% | 4 | Oct 3, 2019 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $17.49 | - | 3 | Mar 22, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $239.56 | -35.72% | 5 | Mar 13, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $68.52 | +69.29% | 2 | Mar 2, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $3.56 | +2,881.72% | 8 | Jan 24, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $12.00 | +133.33% | 1 | Nov 3, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $183.98 | -55.43% | 2 | Sep 27, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $363.12 | - | 1 | Mar 16, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.79 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.16
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $19.95
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $740.29
Upside: +14.82%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $1.86
Upside: +867.74%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $3.52
Upside: +1,604.55%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $4.33
Upside: +108.09%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $6.14
Upside: +453.75%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $151.69
Upside: +115.57%
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $4.53
Upside: +562.25%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $51 → $71
Current: $1.45
Upside: +4,796.55%
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $411.96
Upside: -31.79%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $1.81
Upside: +343.21%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.67
Upside: +5,785.89%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $262.98
Upside: +12.18%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $89.41
Upside: -3.81%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $28.70
Upside: +67.25%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $14.50
Upside: +106.90%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $35.85
Upside: +100.86%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $2.12
Upside: +135.99%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $73.32
Upside: +36.39%
May 5, 2020
Reiterates: Overweight
Price Target: $28 → $24
Current: $0.53
Upside: +4,402.81%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $134.41
Upside: +49.54%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $44.84
Upside: +89.56%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $8.37
Upside: +282.32%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $126.24
Upside: +71.89%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $14.50
Upside: +231.03%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $17.49
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $239.56
Upside: -35.72%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $68.52
Upside: +69.29%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $3.56
Upside: +2,881.72%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $12.00
Upside: +133.33%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $183.98
Upside: -55.43%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $363.12
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $2.79
Upside: -